Fig. 3
From: GSK3 acts as a switch for transcriptional programs in a model of low-grade gliomagenesis
Increased proliferative capacity and clonogenicity after GSK3 inhibition is associated with RUNX2 overexpression. A Gene ontology analysis of intersected RNA-seq and mass spectrometry data demonstrates significant enrichment for terms associated with cell proliferation among upregulated genes and proteins upon CHIR99021 treatment. B Cell cycle analysis using EdU flow cytometry showing a significant increase in S-phase (p = 0.0008–0.00001) along with a significant reduction of cells in G0/G1 (p = 0.00153–0.002919) and inconsistent reduction of G2/M (p = ns – 0.000025), indicating increased cell cycling (n = 3 biological and 3 technical replicates each). C Treatment of IDH1R132H astrocytes with CHIR99021 significantly enhances clonogenic proliferation (p < 0.0001 – p = 0.0024) (n = 3 biological and 3 technical replicates each). D EnrichR transcription factor analysis reveals RUNX2 among the top 5 transcription factors regulating the expression of both up- and downregulated DEGs. E CPM expression profiles of the top transcription factors identified with EnrichR emphasizes RUNX2 as the only transcription factor significantly upregulated upon GSK3 inhibition